Synthesis of colicin Ia neoglycoproteins: tools towards glyco-engineering of bacterial cell surfaces.
Natasha E HattonLaurence G WilsonChristoph G BaumannMartin A FascionePublished in: RSC advances (2024)
Colicins are antimicrobial proteins produced by certain strains of Escherichia coli that function as offensive weapons against closely-related competitor strains. Their bactericidal properties and narrow bacterial targeting range has made them of therapeutic interest. Furthermore, the applications of engineered non-bactericidal colicins are of interest as a cell surface-directed protein anchor for decorating E. coli with biomolecules. We previously demonstrated that an engineered non-bacteriocidal colicin E9 could be used to label bacterial cells with multiple biomolecules including glycans. Herein we extend our approach to colicin Ia, constructing mannose-presenting colicin la neoglycoproteins, through N-terminal organocatalyst-mediated protein aldol ligation (OPAL), or maleimide ligation targeting an internal cysteine. This work further highlights the potential utility of engineered colicins for non-genetic glyco-engineering of the E. coli cell surface.
Keyphrases
- cell surface
- escherichia coli
- biofilm formation
- induced apoptosis
- cancer therapy
- amino acid
- protein protein
- cell cycle arrest
- staphylococcus aureus
- binding protein
- genome wide
- stem cells
- case report
- signaling pathway
- dna methylation
- climate change
- cell death
- risk assessment
- gene expression
- pseudomonas aeruginosa
- copy number
- drug delivery
- pi k akt
- drug induced